Guidelines for the diagnosis and treatment of basal cell carcinoma : a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
Basal cell carcinoma (BCC) is the most common form of cancer, with a high impact on the public health burden and social costs. Despite the overall prognosis for patients with BCC being excellent, if lesions are allowed to progress, or in a small subset of cases harboring an intrinsically aggressive biological behavior, it can result in local spread and significant morbidity, and conventional treatments (surgery and radiotherapy) may be challenging. When a BCC is not amenable to either surgery or radiotherapy with a reasonable curative intent, or when metastatic spread occurs, systemic treatments with Hedgehog inhibitors are available. These guidelines were developed, applying the GRADE approach, on behalf of the Italian Association of Medical Oncologists (AIOM) to assist clinicians in treating patients with BCC. They contain recommendations with regard to the diagnosis, treatment and follow-up, from primitive tumors to those locally advanced or metastatic, addressing the aspects of BCC management considered as priorities by a panel of experts selected by AIOM and other national scientific societies. The use of these guidelines in everyday clinical practice should improve patient care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
ESMO open - 8(2023), 6 vom: 06. Dez., Seite 102037 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Queirolo, P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Basal cell carcinoma |
|---|
| Anmerkungen: |
Date Completed 01.01.2024 Date Revised 02.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.esmoop.2023.102037 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363714502 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363714502 | ||
| 003 | DE-627 | ||
| 005 | 20240108140756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2023.102037 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1246.xml |
| 035 | |a (DE-627)NLM363714502 | ||
| 035 | |a (NLM)37879235 | ||
| 035 | |a (PII)S2059-7029(23)01278-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Queirolo, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidelines for the diagnosis and treatment of basal cell carcinoma |b a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.01.2024 | ||
| 500 | |a Date Revised 02.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Basal cell carcinoma (BCC) is the most common form of cancer, with a high impact on the public health burden and social costs. Despite the overall prognosis for patients with BCC being excellent, if lesions are allowed to progress, or in a small subset of cases harboring an intrinsically aggressive biological behavior, it can result in local spread and significant morbidity, and conventional treatments (surgery and radiotherapy) may be challenging. When a BCC is not amenable to either surgery or radiotherapy with a reasonable curative intent, or when metastatic spread occurs, systemic treatments with Hedgehog inhibitors are available. These guidelines were developed, applying the GRADE approach, on behalf of the Italian Association of Medical Oncologists (AIOM) to assist clinicians in treating patients with BCC. They contain recommendations with regard to the diagnosis, treatment and follow-up, from primitive tumors to those locally advanced or metastatic, addressing the aspects of BCC management considered as priorities by a panel of experts selected by AIOM and other national scientific societies. The use of these guidelines in everyday clinical practice should improve patient care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a GRADE | |
| 650 | 4 | |a basal cell carcinoma | |
| 650 | 4 | |a guidelines | |
| 650 | 4 | |a keratinocyte carcinoma | |
| 650 | 4 | |a skin cancer | |
| 650 | 7 | |a Hedgehog Proteins |2 NLM | |
| 700 | 1 | |a Cinquini, M |e verfasserin |4 aut | |
| 700 | 1 | |a Argenziano, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bassetto, F |e verfasserin |4 aut | |
| 700 | 1 | |a Bossi, P |e verfasserin |4 aut | |
| 700 | 1 | |a Boutros, A |e verfasserin |4 aut | |
| 700 | 1 | |a Clemente, C |e verfasserin |4 aut | |
| 700 | 1 | |a de Giorgi, V |e verfasserin |4 aut | |
| 700 | 1 | |a Del Vecchio, M |e verfasserin |4 aut | |
| 700 | 1 | |a Patuzzo, R |e verfasserin |4 aut | |
| 700 | 1 | |a Peris, K |e verfasserin |4 aut | |
| 700 | 1 | |a Quaglino, P |e verfasserin |4 aut | |
| 700 | 1 | |a Reali, A |e verfasserin |4 aut | |
| 700 | 1 | |a Zalaudek, I |e verfasserin |4 aut | |
| 700 | 1 | |a Spagnolo, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 8(2023), 6 vom: 06. Dez., Seite 102037 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:6 |g day:06 |g month:12 |g pages:102037 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2023.102037 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 6 |b 06 |c 12 |h 102037 | ||